The Association of C-Reactive Protein and CRP Genotype with Coronary Heart Disease: Findings from Five Studies with 4,610 Cases amongst 18,637 Participants by Lawlor, DA et al.
The Association of C-Reactive Protein and CRP Genotype
with Coronary Heart Disease: Findings from Five Studies
with 4,610 Cases amongst 18,637 Participants
Debbie A. Lawlor1,2*, Roger M. Harbord2, Nic J. Timpson1,2, Gordon D. O. Lowe3, Ann Rumley3, Tom R.
Gaunt2, Ian Baker2, John W. G. Yarnell4, Mika Kivima¨ki5, Meena Kumari5, Paul E. Norman6, Konrad
Jamrozik7, Graeme J. Hankey8, Osvaldo P. Almeida9, Leon Flicker9, Nicole Warrington10, Michael G.
Marmot5, Yoav Ben-Shlomo2, Lyle J. Palmer1,10, Ian N. M. Day1,2, Shah Ebrahim11, George Davey Smith1,2
1MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, United Kingdom, 2Department of Social Medicine, University of Bristol,
Bristol, United Kingdom, 3Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 4Department of Epidemiology and Public
Health, The Queen’s University of Belfast, Belfast, United Kingdom, 5Department of Epidemiology and Public Health, University College London, London, United
Kingdom, 6 School of Surgery and Pathology, University of Western Australia, Perth, Australia, 7 School of Population Health, University of Queensland, Herston,
Queensland, Australia, 8 School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, 9Western Australian Centre for Health & Ageing,
University of Australia, Perth, Australia, 10 Laboratory for Genetic Epidemiology, Western Australian Institute for Medical Research and University of Western Australia
Centre for Medical Research, University of Western Australia, Perth, Australia, 11Department of Epidemiology & Population Health, London School of Hygiene & Tropical
Medicine, London, United Kingdom
Abstract
Background: It is unclear whether C-reactive protein (CRP) is causally related to coronary heart disease (CHD). Genetic
variants that are known to be associated with CRP levels can be used to provide causal inference of the effect of CRP on
CHD. Our objective was to examine the association between CRP genetic variant +1444C.T (rs1130864) and CHD risk in the
largest study to date of this association.
Methods and Results: We estimated the association of CRP genetic variant +1444C.T (rs1130864) with CRP levels and with
CHD in five studies and then pooled these analyses (N= 18,637 participants amongst whom there were 4,610 cases). CRP was
associated with potential confounding factors (socioeconomic position, physical activity, smoking and body mass) whereas
genotype (rs1130864) was not associated with these confounders. The pooled odds ratio of CHD per doubling of circulating
CRP level after adjustment for age and sex was 1.13 (95%CI: 1.06, 1.21), and after further adjustment for confounding factors it
was 1.07 (95%CI: 1.02, 1.13). Genotype (rs1130864) was associated with circulating CRP; the pooled ratio of geometric means of
CRP level among individuals with the TT genotype compared to those with the CT/CC genotype was 1.21 (95%CI: 1.15, 1.28)
and the pooled ratio of geometric means of CRP level per additional T allele was 1.14 (95%CI: 1.11, 1.18), with no strong
evidence in either analyses of between study heterogeneity (I2 = 0%, p.0.9 for both analyses). There was no association of
genotype (rs1130864) with CHD: pooled odds ratio 1.01 (95%CI: 0.88, 1.16) comparing individuals with TT genotype to those
with CT/CC genotype and 0.96 (95%CI: 0.90, 1.03) per additional T allele (I2,7.5%, p.0.6 for both meta-analyses). An
instrumental variables analysis (in which the proportion of CRP levels explained by rs1130864 was related to CHD) suggested
that circulating CRP was not associated with CHD: the odds ratio for a doubling of CRP level was 1.04 (95%CI: 0.61, 1.80).
Conclusions: We found no association of a genetic variant, which is known to be related to CRP levels, (rs1130864) and
having CHD. These findings do not support a causal association between circulating CRP and CHD risk, but very large,
extended, genetic association studies would be required to rule this out.
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Introduction
It remains unclear as to whether C-reactive protein (CRP) is
causally related to coronary heart disease (CHD). Higher levels of
CRP are associated with known risk factors for CHD, and these
might confound the purported causal link between CRP and
CHD.[1–6] Furthermore, it is possible that reverse causality-where
either CHD risk factors or pre-symptomatic CHD raise the
circulating level of CRP–explains at least some of the associa-
tion.[7] Whilst confounding and reverse causality might mean that
the association seen in observational studies overestimates the true
causal association, attenuation by errors (also known as regression
dilution bias) might have resulted in an underestimate of the true
causal association of CRP with CHD in these studies.
It has been suggested that the exploitation of the principles of
Mendelian inheritance can be used to determine unconfounded
and unbiased estimates of associations between non-genetic risk
factors and disease outcomes,[8–10] and that this ‘‘Mendelian
randomization’’ approach could provide useful insights into the
nature of the association between CRP and CHD.[11] In this
approach, the association of a genotype that influences the
modifiable risk factor of interest (in this case CRP) with outcome
(CHD) is explored. Since heritable units are randomly assigned at
conception, genotypes within them should not be associated with
confounding factors, such as smoking and socioeconomic circum-
stances, nor will the genotype be affected by disease processes that
influence CRP levels.[8–10] Thus, the association between a
genotype that is associated with circulating CRP levels and CHD
provides a robust test of whether circulating CRP is causally
related to CHD. A test that will not be biased by confounding,
reverse causality or attenuation by errors (regression dilution
bias).[8–10]
This approach was used by Casas et al.[12] to assess the
association between CRP level and CHD among 3155 European
men (985 CHD cases). That study suggested that there was no
strong evidence for a causal association between CRP levels and
CHD but the authors acknowledged that pooling of larger studies
was required to increase confidence in this conclusion.[12] A
number of other studies, which have not directly employed
Mendelian randomization approaches and have included between
210 to 1062 CHD cases, have also found genetic variants within
the CRP gene to be unrelated to prevalent and incident CHD
events, despite these variants being associated with CRP
levels.[13–17]
In a recent prospective nested case control study there were no
associations between four out of five common haplotypes in CRP
with CHD risk, despite associations of these haplotypes with CRP
levels.[13] The only haplotype that was associated with CHD risk
in that study showed an association in the opposite direction to
that predicted by its association with CRP levels; the haplotype
was associated with lower CRP levels but greater CHD risk.[13] In
another study that typed 7 SNPs in CRP there were no associations
with CHD events except in one sub-group analysis: AA genotype
of the triallelic SNP rs3091244 was associated with prevalent
coronary heart disease in non-Hispanic white individuals.[18]
Such sub-group analyses should be treated with caution unless
replicated in independent samples. Finally, Lange and colleagues
found differential associations of 4 SNPs in CRP with cardiovas-
cular disease events.[19] One SNP (1919A/T) was associated with
non-fatal stroke and all cardiovascular disease mortality in white
participants, but was not associated with other cardiovascular
outcomes (including CHD and carotid intima media thickness) in
whites or with any cardiovascular outcomes in Afro-American
participants.[19] A second SNP (790A/T) was associated with
acute myocardial infarction in Afro-American participants on-
ly.[19]
In addition to its importance in understanding the causal role of
CRP with CHD, it has also been suggested that determining the
association of variation in CRP with CHD may be beneficial in its
own right.[20] In a recent review, Hage and Szalai noted the
paucity and inconsistencies of studies examining SNPs in CRP with
cardiovascular endpoints, but suggested that if it could be
established that variants in CRP were robustly associated with
CHD events then CRP gene profiling could have clinical utility in
disease prediction.[20]
The aim of the present study, and a companion paper,[21] is to
expand previous work that has attempted to use genetic variation
in CRP to provide causal inference about the effect of CRP on
CHD and to explore whether there is likely to be potential for
using CRP gene profiling in the prediction of CHD. Ours is the
largest analyses to date to examine the association of variation in
any CRP SNP or haplotype with CHD (we examine association
with one SNP rs1130864); our analysis includes 18,637 partici-
pants with 4,610 CHD cases. The companion paper uses data
from one of the 5 studies included here to examine the association
of genetic variation in CRP with carotid intima media thick-
ness.[21] Thus, that paper answers a related important question
concerned with the nature of the association of CRP with
atherogenesis. If our paper shows an association of variation in
CRP SNP rs1130864 with CHD then the companion paper will
contribute to understanding whether this association is due to an
association of genotype with atherogenesis, plaque rupture or
both.
Methods
Data from the British Women’s Heart and Health Study
(BWHHS),[22] the Caerphilly study,[23] the Speedwell study,[23]
the Whitehall II study[24] and the Health in Men Study
(HIMS)[25] were used. Details of each study population are
provided in the supplementary material on the journal website
(Text S1) and summarised in table 1.
Assessment of CHD
Since our main analyses are concerned with the association of
CRP genotype with CHD, and the association of genotype with
later outcomes cannot be explained by reverse causation or
confounding, we have used a combined outcome of prevalent
CHD (i.e. cases were identified at the same time that CRP was
measured and blood samples for DNA were extracted) and
incident CHD (i.e. cases occurred after CRP assessment and DNA
extraction) for all of our main analyses. However, we also checked
that associations were similar for prevalent cases only and for
incident cases only.
In the BWHHS prevalent cases were any women with self-
report of a doctor diagnosis of angina or myocardial infarction,
evidence in the medical record review at baseline of either of these
diagnoses, or ECG-defined ischemia. Incident CHD was defined
as either death from CHD (ICD10 codes I20–I25) or evidence of
new angina or myocardial infarction in medical record reviews.
In Caerphilly and Speedwell prevalent CHD was defined as any
man with ECG-defined ischemia or self-report of doctor diagnosed
myocardial infarction or angina at baseline and incidence CHD as
ECG-defined ischemia at any follow-up examination, self-report
or medical record evidence of acute MI (WHO criteria), or death
from CHD (ICD 9: 410–414).
In the Whitehall II study, prevalent CHD was ascertained by
questionnaire items on chest pain and a physician’s diagnosis of a
CRP Gene, CRP and CHD
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heart attack.[26] For any participant who indicated that they had
a physician diagnosis of myocardial infarction their medical
records were reviewed and the myocardial infarction only
confirmed if it met MONICA criteria,[27] based on electrocar-
diographic findings, biomarkers of myocardial necrosis and a
history of chest pain in the participant’s medical records. Similarly
for participants whose questionnaire response indicated that they
suffered with angina, this was corroborated in medical records or
by abnormalities in a resting electrocardiogram (ECG), an exercise
ECG, or a coronary angiogram.[26] Only cases of myocardial
infarction or angina that were confirmed in medical records or by
examination findings were classified as a case.
In the HIMS, prevalent CHD was defined as questionnaire-
reported coronary symptoms, bypass surgery or angioplasty, or
evidence from the Western Australia Linked Data System of a
non-fatal CHD event. The Western Australian Linked Data
System keeps a record of all inpatient admissions and all deaths in
the State.[28] Incident cases were men who were free of CHD at
baseline, but had a later health contact due to non-fatal or fatal
CHD during the follow-up period. Relevant ICD 9 and 10 codes
(see above) were used to identify prevalent and incident cases from
the Western Australian Linked Data System.
Genotyping and CRP assays
We assessed the association of +1444C.T SNP (rs1130864) in
the 39 untranslated region of CRP with CRP and CHD in these
studies. This SNP was chosen because it has been shown to be
consistently related to CRP levels and is therefore a robust
instrument for exploring the causal association of CRP levels with
disease outcomes.[12,20,29–32] Furthermore, this is the SNP that
was used in the recent Mendelian randomization study to examine
CRP association with CHD,[12] and it was the one CRP SNP that
had been typed in all of our new studies. Full details of how
genotyping was undertaken and CRP measured for each study are
provided in the supplementary material on the journal website
(Text S1).
Assessment of potential confounders
In all cohorts weight (without shoes and in light clothing) and
height were assessed using standard research procedures and used
to calculate body mass index (kg/m2). Information on occupation
(to determine socioeconomic position), smoking and physical
activity were determined from standard questionnaires.
Ethical issues
All studies had research ethics committee approvals. All
participants provided informed consent to participate in the
studies. In BWHHS 8 women declined consent for the biological
samples to be used for genetic analyses and these women have not
been genotyped.
Statistical analysis
All analyses were conducted only on those with complete data
for genotype, CRP levels and CHD (see table 1 for numbers). For
each cohort Hardy-Weinberg equilibrium was tested on a
contingency table of observed-versus-predicted genotypic frequen-
cies using an exact test.[33] Natural logarithmic transformation of
CRP was undertaken to ensure that residuals were approximately
normally distributed in regression models.
In the main analyses we used a recessive genetic model
(comparing those who were TT homozygotes for rs1130864 to C
allele carriers). The main rationale for this was that the previously
published Mendelian Randomization study [12] to examine this
association used a recessive model and we wished to pool results
from that study with those from our new studies. However, the
association of rs1130864 with CRP concentration in our in-house
studies and previous publications supports an additive (per T
allele) genetic model. Therefore we repeated analyses for our in
house study using an additive model in order to examine whether
this would have changed our main conclusions.
Linear and logistic regressions were performed to examine the
associations of potential confounding factors with CRP concen-
tration and genotype. Linear regression was used to assess the
association between genotype and log CRP, which is presented as
the ratio of geometric mean comparing those who were TT
homozygotes for rs1130864 compared to C allele carriers (or per T
allele). Logistic regression was used to assess the association
between log CRP and any (prevalent or incident) CHD, which is
presented as the age adjusted odds ratio per doubling of CRP.
Random effects meta-analyses were used to pool results from
individual studies. Each individual cohort reported in the meta-
analysis undertaken by Casas et al.[12] was treated as a separate
study in order to consistently model the between-study heteroge-
neity. Heterogeneity was assessed using the I2 measure that
describes the percentage of total variation in the pooled estimate
that is due to between study heterogeneity.[34]
Additional information on statistical analyses, including the
instrumental variables analyses, and strengths and limitations of
this method, are provided in the supplementary material on the
journal website (Text S1).
Results
Our analyses included 18,637 participants, of whom 4,610 were
CHD cases. Across all studies 48% of participants were
homozygous for the C allele, 43% were heterozygotes and 9%
were homozygous for the T allele; the T allele frequency was 0.31
and the overall HWE test result (combining genotype frequencies
from all of the studies in table 1) was p= 0.81. Within each study,
except Whitehall II, there was no evidence for departure from
HWE (see table 1). Because rs1130864 was not in the HWE in
Whitehall II study, in that study the SNP was re-genotyped from
678 samples in a different laboratory and the results called by a
researcher who was blind to the original results. The mismatch
rate was 0.5%. In addition a repeated blood sample was obtained
from 553 participants from which DNA was extracted and the
SNP re-measured. The error rate was less than 1%. The departure
from HWE in Whitehall II suggests that there were approximately
50 fewer T allele homozygotes observed in this sample when
compared to expected frequencies assuming HWE. Our additional
re-genotyping (describe above) suggests that this is most likely due
to random residual (,0.5%) genotyping error, rather than to any
biological selection bias or other populational inhomogeneity.
Association of CRP levels and CRP genotype with
potential confounding factors
Table 2 shows the associations of potential confounding factors
with CRP levels and Table 3 shows the associations of rs1130864
with these potential confounders. In all examined cohorts higher
concentration of CRP was associated with increased prevalence of
obesity and smoking, as well as lower prevalence of physical
activity (Table 2). In BWHHS, Caerphilly, the Whitehall II and
the HIMS study, participants with higher CRP levels were more
likely to be from lower socioeconomic position, but this association
was not apparent in the Speedwell cohort. Genotype was not
associated with these potential confounders in any of the cohorts
(Table 3).
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Table 2. Associations of potential confounding factors with CRP levels in five new cohort studies.
Means (SD) or n (%) of potential confounding factors by thirds of the CRP distribution in 5 cohort studies
BWHHS N=3549 All female
Lowest 1/3 Middle 1/3 Highest 1/3 P trend
Range: 0.16–1.13 mg/l Range: 1.14–3.13 mg/l Range: 3.14–112.0 mg/l
N = 1177 N= 1173 N= 1199
Age mean (SD) years 68.6 (5.5) 68.9 (5.4) 68.9 (5.5) 0.14
BMI mean (SD) kg/m2 25.5 (3.7) 27.7 (4.6) 29.7 (5.5) ,0.001
Obese n (%) 125 (10.7) 294 (25.3) 516 (43.4) ,0.001
Low adult SEP* n (%) 392 (33.3) 440 (37.5) 520 (43.4) ,0.001
Low childhood SEP* n (%) 921 (78.2) 934 (79.6) 980 (81.7) 0.03
Current smoker n (%) 90 (7.7) 123 (10.5) 179 (14.9) ,0.001
Physical activity{ n (%) 513 (44.8) 426 (38.0) 289 (25.4) ,0.001
Caerphilly N=934 All Male
Lowest 1/3 Middle 1/3 Highest 1/3 P trend
Range: 0.17–1.09 mg/l Range: 1.10–2.61 mg/l Range: 2.62–48.1 mg/l
N = 332 N= 308 N= 294
Age mean (SD) years 56.0 (4.3) 56.9 (4.6) 57.6 (4.4) ,0.001
BMI mean (SD) kg/m2 25.4 (3.0) 27.3 (3.4) 27.1 (4.2) ,0.001
Obese n (%) 22 (6.7) 62 (20.3) 51 (18.0) ,0.001
Low adult SEP* n (%) 146 (53.2) 165 (66.5) 165 (68.5) 0.004
Low childhood SEP* n (%) 210 (85.4) 211 (87.6) 208 (92.0) 0.03
Current smoker n (%) 81 (24.4) 99 (32.3) 122 (41.6) ,0.001
Physical activity$ n (%) 124 (37.4) 101 (32.8) 90 (30.6) 0.05
Speedwell N=639 All Male
Lowest 1/3 Middle 1/3 Highest 1/3 P trend
Range: 0.10–0.90 mmol/l Range: 0.91–2.50 mmol/l Range: 2.51–28.90 mmol/l
N = 254 N= 216 N= 169
Age mean (SD) years 56.4 (4.2) 57.3 (4.4) 57.0 (4.3) 0.11
BMI mean (SD) kg/m2 25.5 (2.8) 26.2 (3.0) 26.4 (3.2) ,0.001
Obese n (%) 10 (3.9) 20 (9.3) 19 (11.4) 0.004
Low adult SEP* n (%) 156 (61.4) 125 (57.9) 103 (61.0) 0.85
Low childhood SEP* n (%) NA NA NA NA
Current smoker n (%) 52 (20.5) 73 (33.8) 71 (42.0) ,0.001
Physical activity" n (%) 33 (13.0) 20 (9.3) 13 (7.7) 0.07
Whitehall II N=3696 Male, N=1355 Female
Lowest 1/3 Middle 1/3 Highest 1/3 P trend
Range: 0.08–0.77 mg/L in men; 0.08–
0.90 mg/L in women
Range: 0.78–1.77 mg/L in men;
0.91–2.55 in women
Range: 1.78–114.0 mg/L in men;
2.56–160.0 in women
N= 1680 N= 1686 N= 1685
Age mean (SD) years 60.3 (5.8) 61.0 (6.0) 61.7 (6.0) ,0.001
BMI mean (SD) kg/m2 24.6 (3.3) 26.7 (3.7) 28.6 (4.7) ,0.001
Obese n (%) 98 (5.9) 292 (17.4) 536 (31.9) ,0.001
Low adult SEP{ n (%) 113 (6.8) 139 (8.3) 159 (9.5) 0.01
Low childhood SEP* n (%) 435 (37.8) 528 (44.5) 550 (48.3) ,0.001
Current smoker n (%) 105 (6.3) 155 (9.2) 231 (13.7) ,0.001
Physical activity# n (%) 1447 (87.0) 1410 (84.9) 1388 (83.3) 0.01
HIMS N=4659 All male
Lowest 1/3 Middle 1/3 Highest 1/3 P trend
Range: 0.15–1.26 mg/L Range: 1.27–2.89 mg/L Range: 2.90–182.0 mg/L
N= 1276 N= 1259 N= 1270
CRP Gene, CRP and CHD
PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e3011
Association of CRP levels and CHD
Table 4 shows the association between circulating CRP and
CHD. Associations were of a similar magnitude for prevalent
CHD (CRP levels measured at same time as history of CHD
ascertained) and incident CHD (CRP levels measured before new
cases of CHD) in each cohort, and with a combined outcome of
prevalent and incident CHD. With adjustment for confounders
(body mass index, smoking, socioeconomic position and physical
activity) the positive age and sex adjusted associations attenuated
towards the null in each cohort, though positive associations
remained in BWHHS, Caerphilly and Speedwell. When results
from all five cohorts were pooled in a meta-analysis a doubling of
CRP was associated with an odds ratio of CHD of 1.13 (95%CI:
1.06, 1.21) in age and sex adjusted models (Figure 1) and of 1.07
(95%CI: 1.02, 1.13) in age, sex and confounder adjusted models
(Figure 2). There was evidence of heterogeneity between studies in
both of these meta-analyses (I2 = 80.8% in the age and sex
adjusted analyses and 63.0% in age, sex and confounder adjusted
analyses). None of the percentage of participants who were male in
each study, mean age of study participants, the percentage of cases
that were incident in each study or the percentage of cases that
were hard CHD outcomes (acute MI or death from CHD)
explained between study heterogeneity in either the age adjusted
or the full confounder adjusted meta-analyses (all p-values .0.2).
Association of CRP genotype with CRP levels and with
CHD events
Genotype (rs1130864) was associated with circulating CRP in
all cohorts (Table 1), with the pooled ratio of geometric means
comparing individuals with the TT genotype to those with the
CT/CC genotype being 1.21 (95%CI: 1.15, 1.28) (Figure 3).
There was no detectable between-study heterogeneity in this
analysis (I2 = 0%, p= 0.90). The pooled (for our 5 in-house studies
only) per T allele ratio of geometric means was 1.13 (95%CI: 1.10,
1.16), with no detectable between-study heterogeneity (I2 = 0%,
p= 0.91). Despite the robust associations of rs1130864 with
circulating CRP this variant explained only a small proportion
of its variation: within BWHHS (women only) it explained 0.8%;
within Caerphilly (men only) 0.4%; within Speedwell (men only)
0.6%; within Whitehall II (73% men) 0.4% and within HIMS
(men only) 0.7%.
There was no strong evidence of an association between
rs1130864 and CHD in any of the studies. Table 1 presents
associations, by study, of genotype with a combined outcome of
prevalent and incident CHD; results were the same when
associations were examined for prevalent cases alone and for
incident cases alone. The pooled odds ratio of CHD comparing
individuals with the TT genotype to those with the CT/CC
genotype was 1.01 (95%CI: 0.88, 1.16) (Figure 4). There was
minimal between-study heterogeneity in this analysis (I2 = 7.5%,
p= 0.62). The pooled (for our 5 in-house studies only) per T allele
odds ratio of CHD was 0.96 (95%CI: 0.90, 1.03), with no
detectable between-study heterogeneity in this analysis (I2 = 0%,
p= 0.99).
There was no evidence of correlation between rs1130864-CRP
concentration and rs1130864-CHD estimates from separate
studies on either a scatter plot (not shown) or as measured by
the correlation coefficient of 20.089 (p= 0.83), justifying our
assumption of no correlation in our use of Fieller’s theorem for
estimating the confidence interval for the instrumental variables
analysis (see website supplementary material for methods: Text
S1). Combining the rs1130864-CRP and rs1130864-CHD
summary estimates gave an instrumental variable estimate (see
website supplementary material for methods: Text S1) of the odds
ratio of CHD for a doubling of CRP concentration of 1.04 (95%
CI: 0.61, 1.80). Findings were similar, but with wider confidence
intervals, when incident cases only were included in the
instrumental variables analyses.
Discussion
Meta-analyses of prospective observational studies have dem-
onstrated a positive association between circulating CRP and
CHD risk.[35–37] However, it remains unclear whether this
association is causal or explained by confounding factors or reverse
causality, or even underestimated as a result of attenuation by
errors.[7,38] The best method to establish causality for this
association would be by randomization to an intervention that
Means (SD) or n (%) of potential confounding factors by thirds of the CRP distribution in 5 cohort studies
Age mean (SD) years 76.9 (3.6) 77.0 (3.6) 77.3 (3.7) 0.005
BMI mean (SD) kg/m2 25.7 (3.5) 26.7 (3.4) 27.3 (3.9) ,0.001
Obese n (%) 302 (23.7) 412 (32.7) 529 (41.7) ,0.001
Low adult SEP** n (%) 330 (25.9) 361 (28.7) 410 (32.3) ,0.001
Low childhood SEP n (%) NA NA NA
Current smoker n (%) 43 (3.3) 61 (4.8) 99 (7.8) ,0.001
Physical activity{{ n (%) 396 (31.0) 345 (27.4) 304 (23.9) 0.01
CRP: C-reactive protein; SD: standard deviation; BMI: body mass index; SEP: Socioeconomic position; n: number
NA: data on childhood SEP not available for Speedwell and the HIMS participants
*Defined as manual occupational social class according to British Registrar General’s Classification
{Defined as at least 2 hours per week of moderate of vigorous exercise
$Defined as highest third of the distribution of total energy expenditure derived from the Minnesota Leisure Time Physical Activity
"Defined as participating in regular swimming or morning exercises
{Defined as clerical (lowest) employment grade
#Defined as non-sedentary
**Defined as socioeconomic disadvantage based on a score of less than 1,000 on the Australian 1996 index of disadvantage (http://www.facsia.gov.au/research/prp08/
PRP_No_08.pdf)
{{Defined as two or more episodes of vigorous activity per week
doi:10.1371/journal.pone.0003011.t002
Table 2. cont.
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altered CRP levels but did not affect any other cardiovascular risk
factors. To our knowledge no such trials have been conducted.
The use of genetic variants as instrumental variables to determine
the causal association between circulating CRP and CHD
provides an alternative to such a randomized controlled trial,
with the advantage that this approach can be performed in
existing datasets and may be more generalisable than a
randomized controlled trial.[8,9,10] It has also been suggested
that CRP genetic profiling might have clinical utility in predicting
CHD risk.[20]
In this study of 4,610 cases (the study with the largest numbers
to date to examine the association of variation in CRP with CHD),
we present evidence that higher circulating CRP level is unlikely to
be an important causal risk factor for CHD. We found no
association of a genetic variant (rs1130864) in CRP with CHD
events, despite this variant being consistently associated with
circulating CRP. Using rs1130864 to explore the causal
association of CRP levels with CHD risk is valid since individuals
who are homozygous for the T allele (TT genotype) will have
experienced on average higher levels of circulating CRP over their
lifetime than other individuals (CT or CC genotype),[39] but
potential confounding factors will be evenly distributed between
these two groups of individuals (TT versus CT or CC), as
demonstrated for all our cohorts in table 3. Thus, the association
of rs1130864 with CHD cannot be influenced by reverse causality,
attenuation by errors or confounding. [8,9,10,40] In this respect,
our analysis of the association of rs1130864 with CHD can be
compared to a randomised controlled trial of individuals who have
been randomly allocated (or not) to a 21% higher CRP level on
average across their lives, given that our pooled ratio of geometric
means of CRP by genotype was 1.21.
The assumptions underlying the Mendelian randomization
approach is that the genetic variant is associated with the
modifiable risk factor (circulating CRP levels in this example)
and that it is not related to the outcome of interest (CHD) other
than through its association with the modifiable risk factor (i.e.
there are no confounding factors relating genotype to CHD and
genotype is not related to CHD through other pathways).[8,9,10]
Table 3. Associations of potential confounding factors with
CRP gene (+1444C.T) in five new cohort studies.
Means (SD) or n (%) of potential
confounding factors by genotype in
BWHHS
N=3549 All female
BWHHS N=3549 All female
CC or CT TT p
N=3236 N= 313
Age mean (SD) years 68.8 (5.5) 68.9 (5.4) 0.61
BMI mean (SD) kg/m2 27.7 (4.9) 27.6 (5.3) 0.74
Obese n (%) 855 (26.6) 80 (25.8) 0.76
Low adult SEP* n (%) 1236 (38.2) 116 (37.1) 0.69
Low childhood SEP* n (%) 2587 (79.9) 248 (79.2) 0.76
Current smoker n (%) 358 (11.1) 34 (10.9) 0.91
Physical activity{ n (%) 1133 (36.5) 95 (32.1) 0.14
Caerphilly N=934 All Male
CC or CT TT p
N=830 N= 104
Age mean (SD) years 56.8 (4.5) 57.0 (4.6) 0.71
BMI mean (SD) kg/m2 26.6 (3.7) 26.4 (3.0) 0.63
Obese n (%) 126 (15.4) 9 (8.8) 0.08
Low adult SEP* n (%) 430 (64.3) 46 (57.5) 0.24
Low childhood SEP* n (%) 564 (89.0) 65 (82.3) 0.09
Current smoker n (%) 270 (32.6) 32 (30.8) 0.71
Physical activity$ n (%) 278 (33.5) 37 (35.6) 0.67
Speedwell N=639 All Male
CC or CT TT p
N=580 N= 59
Age mean (SD) years 56.8 (4.3) 57.2 (4.4) 0.52
BMI mean (SD) kg/m2 25.8 (3.0) 26.2 (3.6) 0.32
Obese n (%) 41 (7.1) 8 (13.8) 0.07
Low adult SEP* n (%) 349 (60.2) 35 (59.3) 0.90
Low childhood SEP n (%) NA NA NA
Current smoker n (%) 179 (31.0) 17 (28.8) 0.75
Physical activity" n (%) 57 (9.8) 9 (15.3) 0.20
Whitehall II N=3696 Male; N=1355 Female
CC or CT TT p
N=4625 N= 426
Age mean (SD) years 61.0 (5.9) 60.6 (6.0) 0.18
BMI mean (SD) kg/m2 26.7 (4.3) 26.6 (4.1) 0.76
Obese n (%) 849 (18.4) 77 (18.2) 0.89
Low adult SEP{ n (%) 376 (8.2) 35 (8.3) 0.96
Low childhood SEP* n (%) 1398 (43.8) 115 (40.6) 0.31
Current smoker n (%) 457 (9.9) 34 (8.0) 0.21
Physical activity# n (%) 3889 (85.1) 356 (84.2) 0.59
HIMS N=4659 All male
CC or CT TT p
N=3442 N= 363
Age mean (SD) years 77.1 (3.6) 76.9 (3.6) 0.30
BMI mean (SD) kg/m2 26.6 (3.6) 26.7 (3.7) 0.45
Obese n (%) 1126 (32.7) 117 (32.2) 0.85
Low adult SEP{ n (%) 997 (29.0) 104 (28.7) 0.85
Means (SD) or n (%) of potential
confounding factors by genotype in
BWHHS
N=3549 All female
Low childhood SEP* n (%) NA NA
Current smoker n (%) 184 (5.3) 19 (5.2) 0.93
Physical activity# n (%) 950 (27.6) 95 (26.2) 0.56
CRP: C-reactive protein; SD: standard deviation; BMI: body mass index; SEP:
Socioeconomic position; n: number
NA: data on childhood SEP not available for Speedwell the HIMS participants
*Defined as manual occupational social class according to British Registrar
General’s Classification
{Defined as at least 2 hours per week of moderate of vigorous exercise
$Defined as highest third of the distribution of total energy expenditure derived
from the Minnesota Leisure Time Physical Activity
"Defined as participating in regular swimming or morning exercises
{Defined as clerical (lowest) employment grade
#Defined as non-sedentary
**Defined as socioeconomic disadvantage based on a score of less than 1,000
on the Australian 1996 index of disadvantage (http://www.facsia.gov.au/
research/prp08/PRP_No_08.pdf)
{{Defined as two or more episodes of vigorous activity per week
doi:10.1371/journal.pone.0003011.t003
Table 3. cont.
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The rs1130864 SNP has been consistently shown to be associated
with circulating CRP levels in males and females of European
origin,[12,20,29–31] a finding that we have replicated here.
Furthermore we have previously shown that the rs1130864 SNP is
associated with a shift in the whole distribution of CRP levels and
not an increase, for example, only at the higher end or a decrease
only at the lower end of the CRP distribution.[41] This whole-
population shift in CRP levels should clearly be related to a whole-
population shift in CHD risk if CRP were causally related to CHD
and therefore our null finding is unlikely to be explained by
missing individuals with CRP levels above or below a given
threshold in relation to genotype.
There are strong theoretical bases for believing that CRP
genotype will not be related to socioeconomic and behavioural
confounding factors that tend to distort observational epidemio-
logical studies of this association,[8,9,10,42] and we have
empirically demonstrated here that whilst circulating CRP is
related to these potential confounding factors, genotype is not
(Tables 2 and 3).
The variant that we have used in this study is in close linkage
disequilibrium (LD) with variation within a transcription factor
binding site located 59 of CRP that is associated with circulating
concentrations of CRP and thought to be functional.[43–45] It is
unlikely that this functional variant, or one in close LD with it, will
have pleiotropic effects. It is possible that another variant in
another gene near CRP is in LD with rs1130864 and provides
another pathway to CHD. To explain our null result in the context
of circulating CRP being truly causally related to CHD this
alternative pathway would have to result in a decrease in CHD
risk by a magnitude that exactly reversed the posited causal
influence of circulating CRP on CHD risk. However, rs1130864
exhibits no major LD (correlation R2.0.2) with SNPs in any other
gene in its genomic region, except with a nearby gene
(ENSG00000196401) identified in Ensembl and HapMap
R2= 0.8, but not shown in Entrez. For lower levels of LD (i.e.
with R2,=0.2), the effect of any confounding gene on CHD
would have to be so large as to be implausible (no such gene has
been found in any CHD genome wide studies to date [46–48]).
Variant ENSG00000196401 (XR 017178.1) shows sequence
similarity to ribosomal protein L27 (LOC646446) mRNA, which
is widely expressed. However, there is no strong evidence that
ribosomal proteins in general, ribosomal protein L27 specifically,
nor ENSG00000196401 gene are associated with CHD risk. Of
note, none of the recent genome-wide association studies identified
variants in ENSG00000196401 as being related to CHD risk.[46–
48] It is therefore unlikely that the variant we have examined here
(rs1130864) is linked via alternative molecular genetic pathways to
CHD risk in such a way that these alternative pathways completely
counter balance an important circulating CRP causal effect on
CHD.
A number of SNPs related to CRP levels have been identified in
CRP and we would have had greater statistical power for our
instrumental variables analyses had we constructed haplotypes
using several SNPs as in one of our previous papers.[32] However,
we were limited here to using a SNP that was typed in all studies
included in the analyses. This should not have biased our results,
which are consistent with other studies showing that genetic
variation in several SNPs in CRP are not associated with CHD in
the way predicted by their association with CRP levels (see
introduction and further discussion below).
Within each of our cohort studies participants are described as
being ‘white’, ‘Caucasian’, or of ‘European’ origin and the
consistency of association between rs1130864 and both CRP
levels and CHD events across our studies suggests that population
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stratification is unlikely to have importantly confounded our
genetic association results. Developmental canalisation (the process
by which target receptors or organs develop differently in response
to varying levels of the exposure of interest during key
developmental periods) might limit the Mendelian randomization
process. The extent to which this occurs with modest effects such
as the differences in CRP level by genotype is unclear.[10]
For our main analyses we combined incident and prevalent
cases. In conventional observational epidemiology incident cases
are important for making causal inference and minimising any
bias due to reverse causality. However, in genetic association
studies reverse causality is not possible and survivor bias very
unlikely.[8,9,10] Repeating our analyses with incident cases only
did not substantively alter any of the point estimates for any of our
analyses.
There was important heterogeneity between individual studies
in the association of circulating CRP with CHD that was not
explained by differences in the distribution of sex, age or the
proportion of incident cases between studies. Adjustment for
potential confounding factors reduced heterogeneity but some
remained even in the confounder adjusted analyses, suggesting
that residual confounding in some studies might explain this
heterogeneity. Since our Mendelian randomization study relates
the proportion of circulating CRP that is explained by rs1130864
to CHD risk, and there was no between study heterogeneity in the
association of this genetic variant with CRP levels or with CHD,
our Mendelian randomization results are unaffected by between
study heterogeneity in the observational association of CRP with
CHD.
Our instrumental variables analysis uses the proportion of the
variation in CRP that is explained by rs1130864 to provide an
estimate of causal effect that is not biased by confounding, reverse
causality or attenuation by errors. However, the advantage of this
approach of being less biased than a conventional multivariable
regression analysis comes at the cost of reduced precision.
Although the point estimate of the odds ratio per doubling of
CRP from the instrumental variables analysis was virtually null
(1.04), the 95% confidence interval (0.61, 1.80) includes the
observational association, and the association found in the most
recent meta-analysis of observational studies.[37] The confidence
interval for the instrumental variables analysis is much wider than
the confidence interval from the observational analyses presented
here or in previous meta-analyses.[37] An alternative to the
instrumental variable analyses in Mendelian randomization studies
is to compare the observed genetic-disease association to that
expected from the best observational studies, as done recently by
Casas et al.[12] Whilst this approach appears to provide more
precise estimates of the causal association of CRP with CHD and
does not require that all studies included in the analyses have
measurements of all three of CRP levels, CRP genotype and CHD,
the level of precision is in fact spurious since it does not fully
account for the relatively small proportion of total variation in
CPR accounted for by genotype and does not include uncertainty
from all analyses.[10]
Figure 1. Pooled age and sex adjusted odds ratio (95% confidence interval) of CHD per doubling of CRP levels. Results from 5 cohort
studies of 13, 978 participants of whom 3,625 were CHD cases (prevalent or incident).
doi:10.1371/journal.pone.0003011.g001
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The fact that rs1130864 explains less than 1% of the variation in
CRP within each of our studies, whilst affecting statistical precision
is unlikely to result in bias. As noted previously,[8,9,10] many
medications that are used in randomised controlled trials to
determine causality explain a similarly small proportion of
variation in the potentially causal risk factor, but with adequate
sample sizes (sometimes, as in our Mendelian randomization study
presented here, obtained only through meta-analysis of data from
a number of trials) provide precise and valid estimates of the causal
effect on clinical endpoints.
For example, blood pressure lowering therapies explain ,2% of
the variation in blood pressure, and in participants who are
randomised to either active blood pressure lowering therapy or
control in randomised controlled trials there will be many other
environmental and genetic factors that influence variation in blood
pressure. Nonetheless, an adequately powered randomised trial of
the effect of blood pressure medication on stroke (or other
cardiovascular outcomes) is, rightly, accepted as unbiased evidence
of the causal effect of blood pressure on stroke risk.[9,10]
With respect to other Mendelian randomization studies, single
SNPs that have been shown to be robustly associated with low
density lipoprotein cholesterol (LDLc), and that explain less than
1% of the variation in circulating LDLc, are robustly associated
with CHD, with the magnitude of this association being somewhat
larger than that predicted from the causal randomised controlled
trial evidence relating statins (which reduce LDLc) to
CHD.[49,50] It has been suggested that the somewhat stronger
effects with these genetic variants relates to the fact that the
randomised difference in LDLc occurring as a result of genetic
variants is life-long, whereas that occurring as a result of statins is
from mid-adult life only.[51,52] Similarly, we have recently shown
that a single SNP in FTO (which again explains less than 1% of
variation in body mass index or total fat mass) is associated with a
wide range of vascular and metabolic outcomes, including fasting
glucose, insulin and lipids, with magnitudes of association that are
the same as would be predicted from the association of FTO with
BMI and of BMI with these outcomes in observational studies and
trials of weight reduction.[53] It would seem odd to us that the
Mendelian randomization approach provides valid causal esti-
mates in examples where causation is not controversial (i.e. the
effect of LDLc on CHD and BMI on fasting glucose) but is
selectively biased in more debatable areas such as that assessed
here and in the companion paper[21] (i.e. the association of CRP
with atherosclerosis and CHD risk).
Our Mendelian randomization findings are consistent with
other studies that have used variants in CRP to explore the causal
association of CRP levels with continuously measured vascular
and metabolic traits and which suggest that CRP is not causally
related to blood pressure, metabolic syndrome components or
carotid intima media thickness.[2,19,32,54] As discussed in the
introduction a number of other studies, which have not directly
employed Mendelian randomization approaches and have includ-
Figure 2. Pooled age, sex and confounder adjusted odds ratio (95% confidence interval) of CHD per doubling of CRP levels. Results
from 5 cohort studies of 13, 978 participants of whom 3,625 were CHD cases (prevalent or incident). Confounders included in multivariable
models = age, sex, smoking, body mass index, physical activity, socioeconomic position.
doi:10.1371/journal.pone.0003011.g002
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ed between 210 to 1062 CHD cases, have also found genetic
variants within the CRP gene to be unrelated to prevalent and
incident CHD events, despite these variants being associated with
CRP levels,[13–17] or have found associations in the opposite
direction to what one would anticipate if higher CRP levels were
causally associated with increased CHD risk,[13] or associations
only in very specific subgroups.[18,19] Whilst such subgroup
analyses might represent true differences in the effect of CRP or
CHD, in general subgroup analyses fail to replicate and should be
treated with caution until replicated in other independent studies.
Furthermore, none of the large genome wide association studies of
CHD have found variation in CRP to be robustly associated with
CHD.[46–48] By contrast variants associated with established risk
factors for CHD (e.g. LDLc) are identified in these genome wide
association studies CHD. Taking these findings together with our
own results–the largest study to date (N= 4160 cases; four times
the largest previous published study) to relate variation in CRP to
CHD–there does not appear to be any strong evidence for an
association of CRP with CHD events, despite its association with
CRP levels. These findings together would suggest that variation
in circulating CRP level is not importantly causally related to
CHD risk and that genetic profiling of CRP is unlikely to be useful
in the prediction of CHD. However, we acknowledge that a very
large genetic (Mendelian randomization) study is required to
definitively demonstrate whether there is no causal association of
CRP with CHD. A newly established collaboration that will
include at least 30,000 CHD events will over the coming years be
able to provide this definitive answer.[55]
In a companion paper we examined the association of 3 tag
SNPs [+1444T.C (rs1130864); +2303G.A (rs1205) and
+4899T.G (rs 3093077)] in the CRP gene with serum CRP and
carotid intima-media thickness (CIMT) in one of the studies
included in this paper (the Whitehall II Study).[21] In that study
there was no independent association of CRP concentration with
CIMT once potential confounding factors had been taken into
account and no evidence from analyses using haplotypes in CRP as
instrumental variables that CRP concentration is causally related
to CIMT.[21] As CIMT is a marker of atherosclerosis, that
paper,[21] together with other studies finding no association of
genetic variation in CRP with CIMT,[19,54] fail to support CRP
as a causal factor for atherosclerosis.
Whilst our findings, together with those of several other studies
described above, suggest that circulating levels of CRP are not
importantly causally related to the development of atherosclerosis or
CHD, an effect of CRP on case-fatality in those with CHD, is
possible. Such an effect is implicated by findings from rodent models
of beneficial effects of post-myocardial infarction CRP lower-
ing,[56] but to our knowledge has not be demonstrated in humans.
Our findings, together with those from a number of other
studies examining the association of genetic variation in CRP with
Figure 3. Association of CRP rs1130864 with CRP levels. Results are the geometric mean (95%CI) of CRP levels comparing individuals with TT
genotype to those with the CT or CC genotype (reference group). The results are from studies of 18, 637 participants of whom 4,610 were CHD cases
(prevalent or incident).
doi:10.1371/journal.pone.0003011.g003
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CIMT and CHD,[12–19,21,54] and with findings from genome
wide association studies of CHD,[46–48] suggest that circulating
CRP does not have an important causal association with CHD. In
our study the instrumental variables result (an odds ratio of 1.04
per doubling of CRP) is our best estimate of causal effect.
However, very large genetic association studies are required to
provide a precise estimate of this association and rule out possible
modest causal effects.[55]
Data Access: DAL had full access to all of the data from the
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